African development action with informed and engaged societies
After nearly 28 years, The Communication Initiative (The CI) Global is entering a new chapter. Following a period of transition, the global website has been transferred to the University of the Witwatersrand (Wits) in South Africa, where it will be administered by the Social and Behaviour Change Communication Division. Wits' commitment to social change and justice makes it a trusted steward for The CI's legacy and future.
 
Co-founder Victoria Martin is pleased to see this work continue under Wits' leadership. Victoria knows that co-founder Warren Feek (1953–2024) would have felt deep pride in The CI Global's Africa-led direction.
 
We honour the team and partners who sustained The CI for decades. Meanwhile, La Iniciativa de Comunicación (CILA) continues independently at cila.comminitcila.com and is linked with The CI Global site.
Time to read
1 minute
Read so far

Mobilize Against Malaria

0 comments

Launched in 2007 by Pfizer, Mobilize Against Malaria is a five-year initiative in Kenya, Ghana, and Senegal that aims to engage and educate treatment providers and patients to improve the use and effectiveness of malaria treatment and patient adherence. Working in collaboration with implementing partners in each of the countries, the initiative focuses on training and building capacity, as well as providing grants, evaluation support, and technical expertise.

Communication Strategies

To lead the overall strategic effort and coordinate global monitoring and evaluation of the programmes, the London School of Hygiene and Tropical Medicine will work in partnership with Pfizer and with local evaluation and implementation partners to share lessons learned and best practices with other organisations addressing the malaria epidemic. Each programme in the three countries aims to reduce the rate of malaria morbidity and mortality by improving malaria symptom recognition, treatment, and referral through training activities and complementary community mobilisation campaigns to improve the quality of treatment and strengthen the demand for care.

 

In Ghana, the informal sector of Licensed Chemical Sellers (LCSs) includes over 7,000 retail outlets that are found in almost every community throughout the country. In rural areas with limited pharmacies and public health facilities, LCSs have become a major source of basic medicines for most Ghanaians. In partnership with Family Health International and Ghana Social Marketing Foundation, LCSs in selected districts will be comprehensively trained to promote effective malaria symptom recognition, proper treatment, and referral of acute cases. The programme will be evaluated by Health Partners Ghana.

 

In Senegal, Intrahealth will train community health workers and nurses serving in Tambacounda Region and document the benefits of malaria treatment messaging in the health system. Additionally, a complementary patient messaging programme aims to teach caretakers to recognise early symptoms of malaria, danger signs, and the need to seek appropriate treatment within 24 hours.

 

In Kenya,  Population Services International (PSI) has been selected to promote symptom recognition and treatment-seeking behaviours at the household level, with an emphasis on pregnant women and children under five, using antenatal clinics in western and coastal provinces as an entry point to these groups. The programme will advocate for a range of services through antenatal care clinics that are simple and are easy to incorporate within the existing health-care system. Great Lakes University will play an integral role in the training efforts. Evaluation by KEMRI/Wellcome Trust led by malaria researcher, Dr. Robert Snow, is planned.

Development Issues

Health.

Key Points
Partners

London School of Hygiene and Tropical Medicine, KEMRI-Wellcome Trust, Population Services International (PSI), Health Partners Ghana, Family Health International/Ghana Social Marketing Foundation (GSMF), Intrahealth International.

Sources

PSI website on December 3 2007 and August 5 2009, and Pfizer Press Release on Business Wire, September 5 2007.